Show simple item record

dc.contributor.authorRopponen, Henni-Karoliina
dc.contributor.authorDiamanti, Eleonora
dc.contributor.authorSiemens, Alexandra
dc.contributor.authorIllarionov, Boris
dc.contributor.authorHaupenthal, Jörg
dc.contributor.authorFischer, Markus
dc.contributor.authorRottmann, Matthias
dc.contributor.authorWitschel, Matthias
dc.contributor.authorHirsch, Anna K H
dc.date.accessioned2021-07-19T10:06:23Z
dc.date.available2021-07-19T10:06:23Z
dc.date.issued2021-03-03
dc.identifier.citationRSC Med Chem. 2021 Mar 3;12(4):593-601. doi: 10.1039/d0md00409j.en_US
dc.identifier.pmid34046630
dc.identifier.doi10.1039/d0md00409j
dc.identifier.urihttp://hdl.handle.net/10033/622942
dc.description.abstractIn the search for new antibacterial compounds, we repositioned an antimalarial compound class by derivatising it based on the so-called "eNTRy" rules for enhanced accumulation into Gram-negative bacteria. We designed, synthesised and evaluated a small library of amino acid modified compounds together with the respective Boc-protected analogues, leading to no substantial improvement in antibacterial activity against Escherichia coli wild-type K12, whereas more distinct activity differences were observed in E. coli mutant strains ΔtolC, D22, ΔacrB and BL21(DE3)omp8. A comparison of the activity results of the E. coli mutants with respect to the known rules related to enhanced activity against Gram-negative bacteria revealed that applicability of the rules is not always ensured. Out of the four amino acids used in this study, glycine derivatives showed highest antibacterial activity, although still suffering from efflux issues.en_US
dc.language.isoenen_US
dc.publisherRoyal Society of Chemistryen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleAssessment of the rules related to gaining activity against Gram-negative bacteria.en_US
dc.typeArticleen_US
dc.identifier.eissn2632-8682
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalRSC medicinal chemistryen_US
dc.source.volume12
dc.source.issue4
dc.source.beginpage593
dc.source.endpage601
dc.source.journaltitleRSC medicinal chemistry
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Ropponen et al.pdf
Size:
824.7Kb
Format:
PDF
Description:
accepted manuscript

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International